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SLE is a complex autoimmune inflammatory disease characterized by pathogenic autoan-
tibody production as a consequence of uncontrolledT–B cell activity and immune-complex
deposition in various organs, including kidney, leading to tissue damage and function loss.
There is a high unmet need for better treatment options other than corticosteroids and
immunosuppressants. Phosphoinositol-3 kinase δ (PI3Kδ) is a promising target in this
respect as it is essential in mediating B- and T-cell function in mouse and human. We
report the identification of selective PI3Kδ inhibitors that blocked B-, T-, and plasmacytoid
dendritic cell activities in human peripheral blood and in primary cell co-cultures (BioMAP®)
without detecting signs of undesired toxicity. In an IFNα-accelerated mouse SLE model,
our PI3Kδ inhibitors blocked nephritis development, whether administered at the onset of
autoantibody appearance or the onset of proteinuria. Disease amelioration correlated with
normalized immune cell numbers in the spleen, reduced immune-complex deposition as
well as reduced inflammation, fibrosis, and tissue damage in the kidney. Improvements
were similar to those achieved with a frequently prescribed drug for lupus nephritis, the
potent immunosuppressant mycophenolate mofetil. Finally, we established a pharmaco-
dynamics/pharmacokinetic/efficacy model that revealed that a sustained PI3Kδ inhibition
of 50% is sufficient to achieve full efficacy in our disease model. These data demonstrate
the therapeutic potential of PI3Kδ inhibitors in SLE and lupus nephritis.
Keywords: PI3Kδ inhibitor, immune response, SLE, lupus nephritis, drug development, pharmacodynamic
biomarker, pharmacokinetic/pharmacodynamic modeling
INTRODUCTION
SLE is a complex autoimmune inflammatory disease that affects
multiple organs with unpredictable flares (1). It is character-
ized by pathogenic autoantibodies, immune-complex deposition
in target tissues, and ensuing inflammation and organ damage.
Although the etiology of SLE is poorly understood, genetic and
environmental factors play an important role and contribute to
the deregulation of both innate and adaptive immune systems. A
hallmark is the breakdown of B- and/or T-cell self-tolerance and
the appearance of autoantibodies directed against nuclear com-
ponents, such as anti-dsDNA antibodies. Autoantibody/antigen
immune-complexes in turn can activate TLR7 and/or TLR9 in
plasmacytoid dendritic cells (pDCs) leading to the production
of IFNα. IFNα stimulates myeloid DC maturation that promotes
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loss of self-tolerance, autoantibody production, immune-complex
formation, and further production of IFNα, sustaining a self-
perpetuating vicious cycle of autoimmunity in SLE. Thirty to
fifty percent of SLE patients develop lupus nephritis that can
lead to renal failure, a major life-threatening complication. Com-
monly used therapies include corticosteroids, immunosuppres-
sants/cytotoxic drugs [such as mycophenolate mofetil (MMF)],
and hydroxychloroquine. These drugs block B-, T-cell, or TLR9
function and improve SLE symptoms, but their long-term use
is associated with moderate to severe side effects. The develop-
ment of novel therapeutics to treat SLE and lupus nephritis has
been challenging due to the complex nature of the disease and
the heterogeneity of clinical manifestation (2). In over 50 years,
belimumab, a human monoclonal Ab that neutralizes B cell-
activating factor (BAFF) was the first new drug approved for the
treatment of SLE (3). By interfering with B cell differentiation,beli-
mumab is believed to prevent autoreactive B cells from becoming
Ab-producing plasma cells thereby decreasing SLE autoantibody
titers. Belimumab has a favorable safety profile but shows only
modest efficacy in SLE and is not approved for lupus nephritis,
suggesting that blocking B cell function alone is not sufficient to
curb the disease. For SLE therapeutics to be highly effective, it
appears that not only B cells but also other key pathogenic com-
ponents, such as T-cells and possibly pDC, TLR, and/or IFNα
activities need to be controlled – without compromising long-term
safety.
Class I phosphoinositide 3 kinases (PI3Ks), comprising α, β,
γ, and δ isoforms, are fundamental components of cell signal-
ing as they generate phosphatidylinositol (3,4,5)-triphosphate at
the plasma membrane that recruits and activates proteins con-
taining phospholipid-binding domains, such as Akt, to initiate
downstream signaling events leading to cell growth, survival,
differentiation, proliferation, migration, or cytokine release (4).
PI3Kδ together with PI3Kα and PI3Kβ isoforms belong to class IA
PI3Ks, which are activated by tyrosine kinase receptors, whereas
PI3Kγ, the only member of Class IB PI3K family, mediates signal-
ing downstream of G-protein-coupled receptors. Unlike PI3Kα
and PI3Kβ, which are ubiquitously expressed, PI3Kδ and PI3Kγ
isoforms show a restricted expression and are found mainly in
hematopoietic and endothelial cells. While PI3Kγplays major roles
in myeloid cell function (5), PI3Kδ is pivotal in mediating B cell
receptor (BCR)- and T-cell receptor (TCR)-mediated responses,
including B cell proliferation, differentiation, homing, Ag pre-
sentation, Ab and cytokine production, T-cell differentiation and
cytokine production (6), and TLR9-induced IFNα production in
pDC (7). All of these activities are considered major pathogenic
contributors in SLE. In addition, PI3Kδ activity confers resis-
tance to activation-induced T-cell death (AICD), a defect that may
contribute to loss of self-tolerance in SLE: two-thirds of studied
patients show enhanced PI3Kδ activation in correlation with dis-
ease activity (8). Indeed, haploinsufficiency of PI3Kδ in mice leads
to defects in T-cell activation, Ab class-switching, and decreased
SLE pathology in Lyn-deficient mice (9). Thus, specific inhibi-
tion of PI3Kδ may provide the appropriate immunomodulation
to control SLE pathology.
Here, we describe the discovery and characterization of
two potent and selective small molecule PI3Kδ inhibitors,
MSC2360844 and MSC2364588. We show that both compounds
were potent inhibitors of PI3Kδ-mediated cell functions of B- and
T-cells, and to a lesser extent pDCs in human primary cell cultures.
In an IFNα-accelerated NZB/W F1 SLE model, MSC2360844 and
MSC2364588 blocked the development of proteinuria and kidney
damage in a dose-dependent manner. In addition, we established a
pharmacokinetic (PK− compound exposure)/pharmacodynamic
(PD − compound effect)/efficacy model. Using this model, we
were able to determine the percentage of required sustained PI3Kδ
inhibition for optimal efficacy. The model and data obtained will
facilitate potential clinical development.
MATERIALS AND METHODS
CHEMICAL SYNTHESIS
MSC2360844, 6-fluoro-3-(morpholin-4-yl carbonyl)-1-[4-
(morpholin-4-yl methyl) phenyl]-1,4-dihydrothiochromeno[4,3-
c]pyrazole 5,5-dioxide, was synthesized in five steps following
procedures described in WO2011058149. As a summary, synthe-
sis was started by reaction of 6-fluoro-thiochroman-4-one with
diethyl oxalate in the presence of sodium ethoxide. The interme-
diate was then cyclized with 4-(4-hydrazinylbenzyl)morpholine
forming a pyrazole ring. The thioether was oxidized to the cor-
responding sulfone by reaction with meta-chloroperbenzoic acid
which was followed by the saponification of the ethyl ester into the
corresponding acid followed by the coupling with morpholine to
give the desired compound.
MSC2364588, (R)-7-fluoro-3-(morpholin-4-yl carbonyl)-1-
[1-(2-morpholin-4-yl ethyl)piperidin-3-yl]-1,4-dihydrothiochro-
meno[4,3-c]pyrazole 5,5-dioxide, was synthesized in nine linear
steps as described in WO2011058149. As a summary, syn-
thesis was started by reaction of 7-fluoro-thiochroman-4-one
with diethyl oxalate in the presence of sodium ethoxide.
The intermediate was then cyclized, in the presence of HCl,
with tert-butyl 3-[2-(tert-butoxycarbonyl)hydrazino]piperidine-
1-carboxylate, that was obtained by reduction of the hydrazone
resulting from the reaction of 1-boc-3-piperidone with tert-butyl-
carbazate, forming a pyrazole ring. The piperidine ring was pro-
tected by reaction with di-tert-butyl dicarbonate and the thioether
was oxidized to the corresponding sulfone by reaction with meta-
chloroperbenzoic acid. The intermediate was then deprotected
in the presence of TFA, separated by chiral chromatogra-
phy, and (R)-7-fluoro-3-(morpholin-4-yl carbonyl)-1-[piperidin-
3-yl]-1,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide was
reacted with chloroacetaldehyde and sodium triacetoxyborohy-
dride. The addition of morpholine in the presence of sodium
iodide and potassium carbonate yielded the desired compound.
COMPOUNDS
MSC2360844 and MSC2364588 were dissolved in DMSO for
in vitro studies and in 0.5% hydroxypropyl methylcellulose
(HPMC) and 0.25% (v/v) Tween 20 in water for in vivo studies by
gavage at indicated concentrations or doses.
BIOCHEMICAL ASSAY
Scintillation proximity assay (SPA) was performed to assess
PI3Kα, β, γ, and δ enzymatic activity using neomycin-coated
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beads (Amersham, Buckinghamshire, UK) with 100µM of phos-
phatidyl inositol in form of lipid micelles as substrates contain-
ing phosphatidyl-l-serine (Sigma) as lipid carrier and 65µM
[γ33P]ATP (10). The scintillation signal was measured in a 384
plate reader, Triluxβ-counter (Perking Elmer, Shelton, CT, USA).
COMPOUND PROFILING IN BioMAP® SYSTEMS
Protocols for compound profiling in complex primary human cell
culture (BioMAP) systems have been reported previously (11–13),
and are described in detail in Section 3 in Supplementary Mate-
rial. Preparation and culture of primary human endothelial cells,
neonatal foreskin fibroblasts (HDFn) and bronchial epithelial cells
(Cell Applications, Inc., San Diego, CA, USA), arterial smooth
muscle cells and keratinocytes (Lonza, Inc., Allendale, NJ, USA)
were as previously described. Positively selected primary normal
human CD19+ B cells and CD4+ T-cells were obtained from All-
Cells (Emeryville, CA, USA). PBMC were isolated from buffy coats
(Stanford Blood Center, Stanford, CA, USA). All primary human
cells utilized in this work were obtained under protocols that were
reviewed by Institutional Review Board(s) (IRB) that operate in
accordance with the requirement of EPA Regulation 40 CFR 26
and HHS Regulation 45 CFR 46 of the US Federal Government
for the protection of human research subjects.
Test compounds were prepared in DMSO, added 1 h before
stimulation of the cells, and were present during the whole
24–144 h stimulation period, depending on system.
The levels of readout parameters were measured by ELISA
(14, 15). Measurement values for each biomarker readout in a
compound-treated sample were divided by the mean value from
eight DMSO control samples (from the same plate) to generate a
ratio. All ratios were then log10 transformed and plotted (BioMAP
profile). Overt cytotoxicity of test compounds was assessed by total
cell protein staining sulforhodamine B (Sigma-Aldrich, St. Louis,
MO, USA) for adherent cells, or by cell viability staining Alamar
Blue (Invitrogen, Carlsbad, CA, USA) for non-adherent cells.
HUMAN SAMPLE
Heparinized human blood or buffy-coat prepared from healthy
donors was obtained from the “Center de transfusion sanguine” of
Geneva (Switzerland). Cryopreserved PBMCs from SLE patients
were obtained from Asterand (Detroit, MI, USA). Both SLE
patients were female with moderate clinical activity (SLEDAI score
of 6 at the day of blood draw) and treated with hydroxychloroquine
and NSAIDs. The patients were 55 and 65 years old. Studies were
approved by Merck Serono ethics committee.
BCR-CROSSLINKING-INDUCED Akt PHOSPHORYLATION IN CELLULAR
ASSAYS
Human B lymphocyte cell line Ramos cells (ATCC #CRL-1923)
were grown in serum-free IMDM medium for 2 h, incubated
with PI3Kδ inhibitors for 20 min, and stimulated with 10µg/ml
anti-IgM (Jackson Immuno Research, West Grove, PA, USA) for
15 min. Cells were fixed with 4% paraformaldehyde and perme-
abilized in 0.2% Triton X-100 in PBS before staining with rabbit
anti-phospho-Akt (pAkt) (Ser473) (Cell Signaling Technology,
Danvers, MA, USA) in PBS containing 4% FCS for 1 h, followed
by mouse anti-human IgM–APC (BD Biosciences Pharmingen,
San Diego, CA, USA) and anti-rabbit IgG-Alexa 488 (Invitrogen,
Carlsbad, CA, USA) for 30 min at room temperature.
Anti-IgM-induced pAkt in human whole blood
Human whole blood was incubated with PI3Kδ inhibitors for
30 min and stimulated with 30µg/ml anti-IgM (Jackson Immuno
Research, West Grove, PA, USA) for 5 min at 37°C. Samples were
fixed with 4% formaldehyde for 8 min and red blood cells were
lysed with 0.16% Triton for 30 min at 37°C followed by perme-
abilization with 50% methanol overnight at −20°C. Cell were
stained with rabbit anti-pAkt (Ser473) followed by the Alexa647-
conjugated F(ab′)2 goat anti-rabbit IgG (Invitrogen, Carlsbad,
CA, USA), and anti-CD19-PE (BD Biosciences Pharmingen, San
Diego, CA, USA). CD19+ cells were gated for pAkt analysis.
Anti-IgD-induced pAkt in mouse whole blood
Whole blood withdrawn from C57BL/6N mice (Charles River Lab-
oratories, L’Arbresle, France) was incubated with PI3Kδ inhibitors
for 30 min and stimulated with goat anti-mouse IgD antiserum
(eBioscience, San Diego, CA, USA) for 7 min at 37°C. Samples
were fixed with 4% formaldehyde for 6 min and red blood cells
were lysed with 0.16% Triton for 30 min at 37°C followed by per-
meabilization with 50% methanol overnight at−20°C. Cells were
stained with rabbit anti-pAkt (Ser473) for 1 h followed by anti-
IgD-FITC, anti-B220-PerCP-Cy5.5 (all BD Biosciences Pharmin-
gen, San Diego, CA, USA), and donkey anti-rabbit IgG-Alexa647
(Invitrogen, Carlsbad, CA, USA) for 30 min at room temperature.
B220+IgD+ cells were gated for pAkt analysis.
BCR-CROSSLINKING-INDUCED CD69 UP-REGULATION IN WHOLE
BLOOD ASSAYS
Anti-IgM-induced CD69 in human whole blood
Human whole blood were incubated with PI3Kδ inhibitors for
30 min and stimulated with 30µg/ml anti-IgM for 18 h before
staining with anti-CD69-PE and anti-CD19-PerCp-Cy5.5 (all BD
Biosciences Pharmingen, San Diego, CA, USA) for 30 min at room
temperature. After red blood cells lysis, CD19+ cells were gated for
CD69 analysis.
Anti-IgM-induced CD69 in mouse whole blood
Whole blood withdrawn from naïve C57BL/6N mice (Charles
River Laboratories, L’Arbresle, France) were incubated with PI3Kδ
inhibitors for 30 min and stimulated with 1/12 goat anti-mouse
IgD antiserum (eBioscience, San Diego, CA, USA) for 4 h before
staining with anti-B220-PerCP-Cy5.5 and anti-CD69-PE (all BD
Biosciences Pharmingen, San Diego, CA, USA) for 30 min at room
temperature. After red blood cells lysis, B220+IgD+ cells were
gated for CD69 analysis.
EX VIVO MOUSE WHOLE BLOOD ASSAYS
PI3Kδ inhibitors were administered to naïve C57BL/6N mice
(Charles River Laboratories, L’Arbresle, France), by gavage at indi-
cated time points before heparinized whole blood was obtained
and divided into two aliquots. One aliquot was incubated with
anti-IgD as stimulation and another PBS as basal control. pAkt
in B cells or CD69 up-regulation on B cell surface of each sample
was measured as described for the in vitro assays. The difference
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between stimulated and basal levels of mean fluorescence intensity
(MFI) was calculated as ∆ value.
PROLIFERATION ASSAY
CD19+ B cells were isolated from PBMC of healthy volunteers
by negative selection using the B cell purification kit II (Miltenyi
Biotech, Bergisch Gladbach, Germany) and following manufac-
turer’s instructions. Purified B cells (with a purity of more than
95%) were incubated with PI3Kδ inhibitors for 1 h, and stim-
ulated with 10µg/ml goat F(ab′)2 anti-IgM (Southern Biotech)
and 10 ng/ml recombinant human IL-4 (Immunotools,Friesoythe,
Germany) for 4 days. [3H] thymidine (1µCi; Perkin Elmer, Shel-
ton, CT, USA) was added for the last 18 h of culture. Proliferation
was assessed by a multiplate beta counter (Perkin Elmer, Shelton,
CT, USA).
CYTOKINE RELEASE ASSAYS
B cell cytokine release assay
CD19+ B cells isolated PBMC of healthy volunteers (with a purity
of more than 95%) were incubated with PI3Kδ inhibitors for
1 h, and stimulated 10µg/ml rabbit anti-human IgA+ IgG+ IgM
(H+ L) (Jackson Laboratories, Bar Harbor, ME, USA), 3µg/ml
CpG ODN 2006 (oligodeoxynucleotides; InVivogen, San Diego,
CA, USA) and 8000 IU/ml of recombinant human IFN-α for 48 h.
Cytokines in the supernatants were measured with Cytometric
Bead Array kits (BD Biosciences Pharmingen, San Diego, CA,
USA).
T-cell cytokine release assay
CD4+CD45RA− memory T-cells (more than 95% purity) were
isolated from PBMC of healthy volunteers by negative selection
using the CD4+ memory cell purification kit (Miltenyi Biotech,
Bergisch Gladbach, Germany). Purified T-cells were incubated
with PI3Kδ inhibitors for 1 h, and stimulated with 5µg/ml anti-
CD3 and 2µg/ml anti-CD28 for 5 days. Cytokines in the super-
natants were measured with Luminex® xMAP® multiplex bead
assay kits (Bio-Rad, Hercules, CA, USA).
Plasmacytoid dendritic cells IFN-α release assay
Plasmacytoid dendritic cells were isolated from PBMC of
healthy volunteers by negative selection using pDC purification
kit (Miltenyi Biotech, Bergisch Gladbach, Germany). Purified
CD123+/CD303+ pDC cells (with more than 95% of purity) were
incubated with PI3Kδ inhibitors for 1 h and stimulated with 1µM
CpG ODN 2395 Type C (InVivogen, San Diego, CA, USA) for 18 h.
IFN-α in the supernatants was measured from the culture super-
natants with Verikine ELISA kit (PBL Assay Science, Piscataway,
NJ, USA).
PK/PD MODELING
An I max PK/PD model describing BCR activation-induced pAkt
response was established using data from in vitro and ex vivo
mouse whole blood assays.
E = E0 − Imax × C/ (IC50 + C) ,
where E represents pAkt response, C compound plasma con-
centration, E0 pAkt upon ex vivo stimulation in the absence of
compound treatment, I max the maximum inhibitory effect, and
IC50, concentration required to achieve 50% of I max in vitro.
ACCELERATED NZB/W F1 MOUSE SLE MODEL
All protocols and procedures were conducted according to Ger-
man animal protection law (Tierschutzgesetz) and were approved
by the local veterinarian authorities (Regierungspräsidium, Darm-
stadt, Germany). Ten-week-old female NZB/W F1 mice (Jack-
son Laboratories, Bar Harbor, ME, USA) were given a single
i.v. injection of 1× 108 IU/100µl of AdV-IFN-α (adenovirus
with mmIfna5_v1 insert, Biofocus, CoA.NL.09.160) in saline or
left untreated (sham). Drug treatments were either initiated at
2 weeks (early intervention regimen) or 4 weeks (late intervention
regimen) post AdV-IFN-α delivery until the end of the exper-
iment (at 10 weeks). Mice (10 per group) were treated once
or twice daily with MSC2360844 at indicated doses or MMF
(Cell Cept, Roche) at 300 mg/kg once daily in NaCl by gav-
age, or BAFF-R-Ig (Merck Serono) at 5 mg/kg, or mouse Fc
(mFc, Merck Serono) at 5 mg/kg as isotype control in PBS by
intraperitoneal injection. Serum and urine samples were col-
lected for anti-dsDNA antibodies (by ELISA) and urinary protein
creatinine ratio (UPCR) (measured by ADVIA 1800) determina-
tion, respectively, on the days indicated. Proteinuria is defined as
UPCR>3.
Histopathology analysis of kidney
Paraffin-embedded H&E-stained 4µm tissue sections were
blindly scored as the sum of the following three systems including
inflammation, glomerular damage, and sclerosis. Inflammation:
Grade 1, mild focal interstitial inflammation; Grade 2, multifo-
cal areas of mild interstitial inflammation; Grade 3, moderate
multifocal interstitial inflammation; Grade 4, significant multifo-
cal interstitial inflammation. Glomerular damage: Grade 1, initial
glomerular lesions; initial lesions are characterized by increased
cellular components in a single to few glomeruli with cellular
proliferation and thickening of basement membrane (membra-
noproliferative/mesangiocapillary); Grade 2, multifocal areas of
glomerular lesions; Grade 3, multifocal areas of glomerular lesions
with significant damage characterized by proliferation of epithelial
cells of capsule of Bowman with compression of glomerular capil-
laries; Grade 4, pronounced multifocal to generalized glomerular
damage (i.e., Grade 3 plus obliteration of Bowman space, glomeru-
lar compression, and hyalinosis). Glomerular sclerosis: Grade 1,
focal mild glomerular sclerosis; Grade 2, multifocal mild glomeru-
lar sclerosis; Grade 3, severe focal glomerular sclerosis; Grade 4,
severe multifocal glomerular sclerosis.
Detection of antibody-secreting cells
ELISpot plates (Merck Millipore, Billerica, MA, USA) were coated
with 10µg/ml goat anti-mouse IgG (Calbiochem). Spleen cells
were harvested and titrated starting with 300,000 cells/well. Cells
were incubated for 5 h and after washing and incubation with sec-
ondary HRP conjugated anti-mouse IgG (Sigma, St. Louis, MO,
USA). ELISpots were developed with AEC staining Kit (Sigma, St.
Louis, MO, USA). ELISpots were counted using ELISPOT reader
(AID, Strassberg, Germany).
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FIGURE 1 | Identification of PI3Kδ inhibitor MSC2360844 and MSC2364588. (A) Chemical structure of MSC2360844. (B) Chemical structure of
MSC2364588. (C) Ramos cells were stimulated with anti-IgM for 15 min. Intracellular pAkt was measured by flow cytometry. Data shown are mean±SEM and
are representative of three experiments.
Determination of anti-dsDNA level
ELISA plates were coated with 10µg thymic DNA (Sigma, St.
Louis, MO, USA). Serum of each animal was titrated to deter-
mine anti-dsDNA antibody levels. The levels of each individual
were calculated as arbitrary units compared to a pooled stan-
dard serum from 22-week-old MRLlpr/lpr mice. Detection was
performed using goat anti-mouse IgG HRP-coupled antibodies
and 3,3′,5,5′-tetramethylbenzidine (Sigma-Aldrich, St. Louis, MO,
USA).
Immunofluorescence staining
Cryosections (5µm) of kidneys were stained for 1 h at room
temperature with FITC-conjugated anti-mouse IgG2a (Southern
Biotech, Birmingham, AL, USA). Images were captured using a
CCD camera (AXIOCamMRm Zeiss, Berlin, Germany) connected
to a Zeiss microscope.
RESULTS
IDENTIFICATION OF NOVEL PI3Kδ-SPECIFIC SMALL MOLECULE
INHIBITORS
We identified a thiochroman series through screening of
a focused kinase inhibitor compound library (60 K) for
the inhibition of PI3Kδ activity. Compounds were selected
from both, commercial and proprietary sources, based on
in-house knowledge of the target. Further hit to lead
optimization efforts resulted in the design and synthesis
of MSC2360844 (6-fluoro-3-(morpholin-4-yl carbonyl)-1-[4-
(morpholin-4-ylmethyl)phenyl]-1,4-dihydrothiochromeno[4,3-c]
pyrazole 5,5-dioxide) (Figure 1A) and MSC2364588 (7-
fluoro-3-(morpholin-4-yl carbonyl)-1-[(3R)-1-(2-morpholin-4-
yl ethyl)piperidin-3-yl]-1,4-dihydrothiochromeno[4,3-c]pyrazole
5,5-dioxide) (Figure 1B). MSC2360844 and MSC2364588 inhib-
ited PI3Kδ enzymatic activity with IC50 values of 145 and 15 nM,
respectively, whereas PI3Kα, PI3Kβ, and PI3Kγwere inhibited only
in the micromolar range (Table 1).
MSC2360844 and MSC2364588 were also highly selective
against a panel of 278 additional kinases (Figure S1 in Supplemen-
tary Material). At 10µM, MSC230844 did not show significant
inhibition (>50%) of any kinase, while MSC2364588 impaired
Hck and PAK3 activity albeit with IC50> 10µM. In addition,
Table 1 | Enzymatic potency of MSC2360844 and MSC2364588 in
human class I PI3K isoforms.
Enzymatic potency IC50 (nM)
Isoform MSC2360844 MSC2364588
PI3K δ 145 15
PI3K α 18,500 7,650
PI3K β 2,850 2,450
PI3K γ >20,000 >20,000
both compounds showed favorable in vitro and in vivo drug
metabolism and pharmacokinetic (DMPK) properties (Tables S1
and S2 in Supplementary Material), leading us to progress
MSC2360844 and MSC2364588 to further pharmacological char-
acterization.
PI3Kδ is the only PI3K isoform that mediates in B cells
Ag receptor-induced Akt phosphorylation (pAkt), a surrogate
marker for PI3K cellular activation (16). MSC2360844 and
MSC2364588 completely abolished BCR-induced pAkt in Ramos
B cells in a concentration-dependent manner with IC50 val-
ues of 280 and 57 nM, respectively (Figure 1C). These values
correlate with their relative enzymatic potency (Table 1) and
cell permeability (Tables S1 and S2 in Supplementary Mater-
ial).
Thus, MSC2360844 and MSC2364588 are effective and selec-
tive PI3Kδ inhibitors in both enzymatic and cellular contexts, with
the latter compound showing 10-fold higher potency.
MSC2360844 AND MSC2364588 INHIBIT SLE-PRONE FUNCTIONS OF
HUMAN PRIMARY CELLS
We assessed the effects of MSC2360844 and MSC2364588 on B-
and T-cells and pDCs, the key contributors to SLE pathogenesis.
To this end, we isolated CD19+ B cells from PBMC of healthy
donors and stimulated them in vitro with F(ab′)2 anti-IgM and
IL-4 for 4 days to induce B cell proliferation. MSC2360844 and
MSC2364588 inhibited B cell proliferation in a concentration-
dependent manner with an IC50 of 48 and 7 nM, respectively
(Figure 2A). To simulate pro-inflammatory conditions observed
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FIGURE 2 | MSC2360844 and MSC2364588 block BCR- and
TCR-mediated responses in lymphocytes andTLR-induced IFNα by
pDC in human primary cells. (A) CD19+ B cells isolated from PBMCs
of healthy donors were stimulated with anti-IgM and IL-4 for 4 days.
Proliferation was measured by [3H]-thymidine incorporation. (B) CD19+
B cells isolated from PBMCs of healthy donors were stimulated with
anti-Ig, CpG ODN 2006, and IFNα for 48 h. Cytokines in the
supernatants were measured with CBA kits. (C) CD4+CD45RA− T-cells
isolated from PBMCs of healthy donors were stimulated with anti-CD3
and anti-CD28 for 5 days. Cytokines in the supernatants were
measured with Luminex kit. (D) CD123+/CD303+ pDC cells isolated
from PBMCs of healthy donors were stimulated with CpG ODN 2395
Type C for 18 h. IFNα in the supernatants were measured with ELISA
kit. Difference between basal and stimulated level was used as 100%.
Data shown are mean±SEM and are representative of at least three
independent experiments.
in SLE patients, we cultured B cells in a cocktail containing F(ab′)2
anti-IgM, CpG, and IFNα for 2 days and measured cytokine levels
in the supernatants. MSC2360844 and MSC2364588 reduced
TNFα, IL-6, and IL-10 with potencies similar to those observed in
the B cell proliferation assay (Figure 2B). Thus, both MSC2360844
and MSC2364588 block B cell function effectively. MSC2364588
was again 10 times more potent as seen before in direct PI3Kδ
enzymatic inhibition.
In SLE, T-cell cytokines such as IL-17, IL-6, TNFα, and IL-
10 are up-regulated and their abundance correlates with dis-
ease activities (17). Both of our compounds inhibited these
cytokines produced by CD4+CD45RA− memory T-cells from
healthy donors upon anti-CD3 and anti-CD28 stimulation
for 5 days in a concentration-dependent manner, again with
MSC2364588 being 10 times more potent than MSC2360844
(Figure 2C). Interestingly, both PI3Kδ inhibitors showed lower
potency (3- to 10-folds) in suppressing T-cell function compared
to B cells.
IFNα is mainly produced by pDCs upon activation of
TLRs and up-regulated in peripheral blood of SLE patients.
IFNα-induced genes have been shown to correlate with disease
severity (18, 19) and PI3Kδ has been shown to mediate TLR9-
induced IFNα release from pDCs (7). In agreement with this,
we could show that MSC2360844 and MSC2364588 suppressed
CpG oligodeoxynucleotide-induced TLR9-mediated IFNα pro-
duction by pDCs (isolated from PBMC from healthy donors)
in a concentration-dependent manner (Figure 2D). While both
compounds showed lower potency in this assay (data not shown)
compared to B- and T-cell inhibition, the relative potency
of MSC2364588 over MSC2360844 is again preserved (five to
sixfolds).
Taken together, both, MSC2360844 and MSC2364588, inhib-
ited PI3Kδ-mediated functions in SLE relevant subsets of primary
human cells. B cell function appeared most susceptible to PI3Kδ
inhibition, followed by T-cells and pDCs. From the fact that
the relative potency of our two compounds was preserved in all
assays, cell types, and in vitro enzymatic activity (MSC2364588 is
consistently 5–10 times more potent than MSC2360844), we con-
clude that the observed cellular effects are due to PI3Kδ-specific
inhibition, not off-target activity.
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FIGURE 3 | MSC2360844 and MSC2364588 block B- andT-cell function
without undesired side effects in 12 BioMAP® systems. MSC2360844
and MSC2364588 at indicated concentrations were tested in 12 human
primary cell co-culture BioMAP® systems with 137 readouts (Section 3 in
Supplementary Material). Mixed primary cells were stimulated with
environmental factors mimicking distinct disease or homeostatic conditions
for 24 to 114 h, respectively. (A,B) Cellular activity profile of MSC2360844 in
(A) and MSC2364588 in (B) in the 12 BioMAP® systems. Levels of proteins
were measured by ELISA and presented as log expression ratios [log10
(parameter value with test compound/parameter value of 0.1%DMSO)]. The
gray area represents the 95% prediction interval of the 0.1% DMSO data.
Significantly altered readouts are annotated. (C) Effects of MSC2360844 and
MSC2364588 on annotated readouts from B–T assays. Level of proliferation
was represented by relative fluorescent units (RFU) of Alamar Blue. Cytokines
were measured by ELISA and presented as artificial unit of optical density at
450 nm (OD450).
MSC2360844 AND MSC2364588 DAMPENED B- AND T-CELL FUNCTIONS
IN BioMAP® SYSTEMSWITH A FAVORABLE SAFETY PROFILE
We next explored the effects of MSC2360844 and MSC2364588
in 12 BioMAP® human primary cell co-culture systems (Section
3 in Supplemental Material). We used a broad concentration
range (from 10 to 33.3µM) to cover both on-target and possi-
ble off-target effects. No signs of cytotoxicity were observed at any
concentration in any of the culture systems.
Significant inhibitory effects of the two compounds were
observed in the B–T system, a B cell/PBMC co-culture activated
with anti-IgM and mild TCR stimulation for 84 h (Figures 3A,B).
This system models both T-cell-dependent B cell activation and
class-switching as would occur in a germinal center, and B-cell-
dependent T-cell responses, such as cytokine release (13). In the
B–T culture system, MSC2360844 and MSC2364588 significantly
and dose-dependently inhibited B cell proliferation and IgG secre-
tion, as well as IL-17A, IL-2, and TNFα release, but had no effect
on IL-6 levels (Figures 3A,B). At concentrations ranging from 30
to 300 nM, MSC2364588 is more potent than MSC2360844 with
respect to all inhibited readouts, showing estimated IC50 values
close to those determined in isolated immune subsets (Figure 3C).
Confirming a direct role of PI3Kδ in T-cell activity, both com-
pounds inhibited IL-17A release in the Th2 culture system, a
co-culture of primary human umbilical vein endothelial cells
(HUVEC) and Th2 blasts stimulated by TCR crosslinking and
IL-2 (Figures 3A,B).
Unexpectedly, in a culture system modeling conditions of
chronic inflammation and fibrosis (HDF3CGF), MSC2360844 at
concentrations above 3.7µM reduced the proliferation of human
dermal fibroblasts stimulated with IL-1β, TNF-α, IFN-γ, EGF,
bFGF, and PDGF-BB for 24 h. Since this inhibitory activity was
neither dose-dependent nor observed with MSC2364588, it likely
represents an off-target effect of MSC2360844 at very high con-
centrations. Intriguingly, this anti-proliferative effect was not
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FIGURE 4 | MSC2360844 and MSC2364588 inhibit BCR-induced signaling
and activation of CD19+ B cells in healthy donors and SLE patients.
(A) Peripheral blood from healthy donors were collected in heparinized tubes
and stimulated with anti-IgM for 5 min. Intracellular pAkt gated on CD19+ cells
were analyzed by flow cytometry. (B) Peripheral blood from healthy donors
were collected in heparinized tubes and stimulated with anti-IgM for 18 h.
CD69 up-regulation on CD19+ cells were analyzed by flow cytometry. Mean
fluorescent intensity (MFI) from basal and stimulated conditions without
inhibitor were used as 100% of activity. Data shown are mean±SEM and are
representative for at least five healthy donors. (C) PBMCs from two SLE
patients were stimulated with anti-IgM for 18 h. CD69 up-regulation on CD19+
cells were analyzed by flow cytometry. Mean fluorescent intensity (MFI) from
basal and stimulated conditions without inhibitor were used as 100% of
activity.
observed in a similar culture system/HDF3CT, in which human
dermal fibroblasts are stimulated with IL-1β, TNF-α, IFN-γ, and
TGFβ for 24 h (Figures 3A,B).
Even at very high doses (33µM), neither of our compounds
exerted any significant effect in any of the other nine co-culture sys-
tems, which included cultures of HUVEC with or without PBMCs,
M1 macrophages, human bronchial epithelial cells, or epidermal
keratinocytes under conditions mimicking chronic inflammation
(Figures 3A,B).
The activity profiles of MSC2360844 and MSC2364588 in these
chronic inflammation relevant co-culture systems suggest that tar-
geted PI3Kδ inhibition dampens specifically pro-inflammatory B-
and T-cell functions without inducing cytotoxicity or undesired
side effects in other cell types,which could limit their use in chronic
inflammatory conditions.
MSC2360844 AND MSC2364588 INHIBIT PHARMACODYNAMIC
BIOMARKERS IN HUMAN PERIPHERAL BLOOD
The importance of monitoring relevant biomarkers to improve
the efficiency of drug development is increasingly recognized. We
identified and validated two PD biomarkers, pAkt and CD69, to
assess target inhibition following in vivo administration of our
PI3Kδ inhibitors. To this end, we quantified the activity of our
compounds on BCR-mediated Akt phosphorylation (pAkt) and
CD69 (early activation surface marker) up-regulation. Assays were
done with whole blood from healthy donors.
MSC2364588 inhibited anti-IgM-induced pAkt in whole blood
with IC50 of 32 nM (Figure 4A), similar to its potency in human
Ramos cells (Figure 1C). MSC2360844, on the other hand, had
IC50 of 1550 nM in whole blood (Figure 4A), approximately five-
fold less potent compared to its IC50 in Ramos cells (Figure 1C).
Besides the inherent difference in potency between the two com-
pounds, these data also reflect their differential human plasma
protein binding: while 100% of MSC2364588 is present in the
unbound fraction in human plasma, only 20% of MSC2360844
is unbound (Table S1 in Supplementary Material). MSC2360844
and MSC2365488 also potently blocked anti-IgM-induced CD69
up-regulation on CD19+ B cells in whole blood, with IC50 of 307
and 21 nM, respectively, in line with their enzymatic and cellular
potencies on PI3Kδ as well as plasma protein binding capaci-
ties (Figure 4B). Thus, MSC2360844 and MSC2365488 blocked
PI3Kδ-mediated early B cell activation in peripheral blood from
healthy donors in a concentration-dependent manner.
Anti-IgM induced a weak but consistent up-regulation of CD69
in PBMCs from SLE patients (Figure 4C) comparable to healthy
donors (data not shown). PBMCs were recovered from cryopreser-
vation and our unpublished data have shown that cryopreser-
vation does not alter the responsiveness of PBMCs to anti-IgM
stimulation. In a concentration-dependent manner, MSC2360844
and MSC2364588 abrogated CD69 up-regulation with IC50 of 59
and 9 nM, respectively, in one donor (Figure 4C, left), and 232 and
12 nM, respectively, in another (Figure 4C, right).
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FIGURE 5 | MSC2360844 and MSC2364588 block the PD
biomarkers in mouse and allow PK/PD modeling. (A,B) In in vitro
assays, blood from naïve C57Bl/6N mice was taken and stimulated
in vitro with anti-IgD. In (A), intracellular pAkt gated on B220+ cells
was measured by flow cytometry and expressed as MFI. Data shown
are mean±SEM and are representative for three experiments. In (B),
surface CD69 gated on B220+ cells was measured by flow cytometry
and expressed as MFI. Data shown are mean±SEM and are
representative for two experiments. (C,D) In ex vivo assays,
MSC2360844 at indicated doses was administered by gavage to naïve
C57Bl/6N mice at indicated time points before whole blood was taken
and stimulated in vitro with anti-IgD. In (C), intracellular pAkt was
measured as in (A). ∆pAkt was calculated by subtracting basal from
stimulated signal. In (D), surface CD69 was measured as in (B).
∆CD69 was calculated by subtracting basal from stimulated signal.
Data are shown as mean±SEM with five mice per group. Data were
analyzed by one-way ANOVA followed by Dunnett’s post-tests
compared with vehicle group. **p<0.01, ***p<0.001. (E)
MSC2360844 concentrations in plasma were plotted against
percentage of pAkt inhibition at 1 h time point in the experiment
described in (C). (F) PK/PD model using percentage of pAkt inhibition
readout based on data obtained from (A,B). Points represent the
average of pAkt (% of inhibition) of five animals at a single time or
dose of a compound.
These data as well as the demonstrated technical feasibility of
the assays qualify pAkt and CD69 as possible mechanistic PD bio-
markers to determine the PK/PD relationship of PI3Kδ inhibitors
in dose finding studies in clinical development.
PK/PD CORRELATION AND MODELING OF MSC2360844 AND
MSC2364588 IN MOUSE
To establish the relationship between plasma exposure of
MSC2360844 and MSC2364588 and their target coverage in vivo,
we evaluated pAkt and CD69 PD biomarkers in mice. We first
developed in vitro and ex vivo mouse whole blood assays for pAkt
and CD69. Anti-IgD rather than anti-IgM was used to induce BCR
activation in mice, because IgD activated a larger B cell popula-
tion and the background noise was lower (data not shown). We
then measured BCR activation-induced Akt phosphorylation in
B220+ B cells (Figure 5A) and surface CD69 up-regulation on B
cells in vitro (Figure 5B). MSC2360844 and MSC2364588 blocked
both readouts completely in a concentration-dependent manner
with average IC50s for MSC2360844: 361 nM for pAkt and 412 nM
for CD69; and for MSC2364588: 35 nM for pAkt and 16 nM for
CD69 (Figures 5A,B). In line with their enzymatic inhibitory
activity, plasma protein binding (Table S1 in Supplementary Mate-
rial) and human cellular activity (Figures 1 and 3), MSC2364588
was approximately 10-folds more potent than MSC2360844 in the
mouse whole blood in vitro assay.
In agreement with the established in vivo PK profile in the
mouse (Table S2 in Supplementary Material), the overall exposure
level of MSC2360844 was approximately 10 times higher than that
www.frontiersin.org May 2014 | Volume 5 | Article 233 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Haselmayer et al. PI3Kδ inhibitors in lupus nephritis
of MSC2364588 (Figures S2A,B in Supplementary Material). Oral
administration of both compounds dose-dependently inhibited
pAkt and CD69, with comparable ED50s of 3 mg/kg at the 1 h
time point, and approximately 10 mg/kg at 2 h. At 4 h, the ED50s
were further increased and at 6 h post administration almost no
effect was detected (Figures 5C,D; Figures S2C,D in Supplemen-
tary Material). The higher exposure of MSC2360844 at equivalent
dose compensated completely for its lower in vitro potency as
compared to MSC2364588.
As shown in Figures S2A,B in Supplementary Material, a dose-
dependent increase in exposure was observed, suggesting linear
pharmacokinetics over the dose range studied. In addition, a
direct relationship, i.e., absence of hysteresis, was observed when
plasma concentrations were correlated to the PD effect, namely
pAkt inhibition (Figure 5E; Figure S2E in Supplementary Mater-
ial). These time-course and dose response data and the estimated
PK/PD parameters (Table S2 in Supplementary Material) led to
the establishment of an I max mathematical model linking plasma
concentrations to pAkt inhibition over time in which a correlation
factor of 0.99 was calculated between predicted versus experimen-
tally measured pAkt inhibition (Figure 5F). Thus, a quantitative
relationship between dosing regimen, exposure, and PD effects of
MSC2360844 and MSC2364588 was identified based on the cor-
relation of ex vivo PD effects and in vitro potency, which allowed
the extrapolation of a fitting mathematical PK/PD model.
MSC2360844 AMELIORATES DISEASE MANIFESTATIONS IN A MURINE
SLE MODEL
NZB/W F1 female mice are genetically predisposed for the
development of a SLE-like phenotype including the production
of autoantibodies (e.g., anti-dsDNA) and the development of
glomerular nephritis (20). The onset of proteinuria in this model is
at about week 40, but can be accelerated and synchronized by ade-
noviral delivery of IFN-α (ADV-IFNα) (21). Using a modification
of the Mathian et al. protocol (21), we injected 1× 108 ADV-IFNα
at 10 weeks of age. IFN-α peaked in the serum 7 days later and
lasted for 1 week in NZB/W F1 female mice (data not shown). At
week 2 post ADV-IFNα administration, these mice had detectable
levels of anti-dsDNA Abs in the serum and developed proteinuria
at week 4 (Figures 6A,B and data not shown) with no mortality
by end of experiment at week 10, while sham mice (no IFNα treat-
ment) were free of any sign of disease at this time (Figures 6A,B,
and data not shown).
MSC2360844 exhibited higher oral availability in mouse (Table
S2 in Supplementary Material), rat, dog, and monkey (data not
shown) than MSC2364588. Human PK prediction based on
allometric scaling suggested that the half-life of MSC2360844
in human would be suitable for once daily dosing, whereas
MSC2364588 was predicted to require twice daily dosing in human
(data not shown). We therefore chose to test MSC2360844 in
(i) early intervention (first autoantibodies in serum), starting at
week 2 post ADV-IFNα delivery with once daily oral administra-
tion of 6.6, 22, or 66 mg/kg MSC2360844 or MMF at 300 mg/kg
(equivalent to clinically efficacious dose) as positive control, and
in (ii) late intervention (onset of proteinuria), starting at week
4 post ADV-IFNα delivery (L) with once daily oral administra-
tion of 66 mg/kg MSC2360844. In early intervention, all doses
of MSC2360844 significantly reduced proteinuria incidence and
severity in a dose-dependent manner compared to vehicle and as
determined by UPCR (Figures 6A,B). Mice treated with 66 mg/kg
MSC2360844 were almost completely protected against protein-
uria, equivalent to MMF-treated mice. Even in late intervention,
66 mg/kg MSC2360844 almost completely abrogated proteinuria
(Figures 6A,B). However, inhibition of BAFF (using BAFFR-
Ig) was effective in this model only following early but not late
intervention as determined by UPCR (Figure 6C).
The protective effects of MSC2360844 were confirmed by his-
tological analysis of the kidneys at the end of the experiment,
showing dose-dependent reduction of inflammation, glomerular
damage, and sclerosis (Figures 6D,E). Consistently, levels of pro-
inflammatory cytokines, IL-6, TNFα, GM-CSF, and IL-1β, and IgG
(immune-complex) deposition in the kidney were also decreased
in a dose-dependent manner (Figure S3 in Supplementary Mater-
ial; Figure 6D).
Compared to sham mice, at week 10, ADV-IFNα-treated
NZB/W F1 mice showed dysregulation of immune cells in the
spleen, with a significant increase in the number of plasma cells,
GL-7+IgG− GC B cells, IgG+ class-switched B cells, and acti-
vated CD4+ and CD8+ T-cells, while naïve CD4+ and CD8+
T-cell numbers were reduced (Table 2). MSC2360844 treat-
ment, dose-dependently, restored homeostatic levels by reducing
the numbers of activated GL-7+IgG−GC B cells, IgG+ class-
switched B cells, and plasma cells, as well as activated CD4+ and
CD8+ T-cells, and by increasing naïve CD4+ and CD8+ T-cells
to the level of sham mice (Table 2). Consistent with reduced
plasma cell numbers, antibody-secreting cells (ASCs) in the spleen
were also decreased significantly in a dose-dependent manner
by MSC2360844 treatment. Both, early and late intervention,
66 mg/kg MSC2360844 groups showed equivalent effects to MMF
(Figure 6F).
There was a tendency of serum anti-dsDNA IgG reduction fol-
lowing early treatment with both, MSC2360844 or MMF, although
this was neither statistically significant nor dose-dependent and no
effect was observed following late treatment with MSC2360844
(Figure 6G). These data indicate dissociation between the level of
anti-dsDNA Ab in the serum, ASCs in the spleen and immune-
complex formation and deposition (Figure 6D).
Overall,MSC2360844 is equivalent to 300 mg/kg MMF at a dose
between 22 and 66 mg/kg with respect to modulation immune cell
responses, protection of kidney function, and reduction of inflam-
mation and tissue damage (Table 2; Figure 6A,B,D,G; Figure S3
in Supplementary Material).
To exclude the possibility that the beneficial effects demon-
strated with MSC2360844 were due to off-target activity at peak
serum concentration following once daily doses, we also tested
MSC2360844 (data not shown) and MSC2364588 (Figure S4 in
Supplementary Material) at half daily dose given twice daily in
early intervention. Equivalent results were obtained, suggesting
that MSC2360844 and MSC2364588 block proteinuria progres-
sion through selective PI3Kδ inhibition. Encouragingly, no drug-
related body weight loss was observed throughout these studies
(data not shown).
To further describe the PK/PD relationship of MSC2360844
under disease conditions, we tested the PD response in the SLE
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FIGURE 6 | MSC2360844 abrogates lupus nephritis development in
accelerated NZB/W F1 SLE model. (A) Incidence of proteinuria and
(B) mean UPCR overtime in mice treated once daily with MSC2360844
at 6.6, 22, or 66 mg/kg, or MMF at 300 mg/kg with an early dosing
regimen, or MSC2360844 at 66 mg/kg with a late dosing regimen (L).
(C) UPCR over time in mice treated with BAFF-R-Ig or mFc as control.
(D) Kidney sections obtained at the end of experiment were stained
with H&E (upper panel) or immunofluorescence (lower panel) with
anti-IgG2a FITC Ab. Magnification, 200×. (E) Histopathological scores in
(Continued)
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FIGURE 6 | Continued
(D) (upper panel). Each dot represents one mouse. Bar represents
mean value. (F) ASCs in the spleen measured with ELISpot at the end
of experiment. Each dot represents one mouse. Bar represents mean
value. (G) Levels of anti-dsDNA IgG at the end of experiment. Each dot
represents one mouse. Bar represents mean value. (H) Ex vivo
anti-IgD-induced CD69 up-regulation on B220+ cells in whole blood 1 h
post last dosing after 2 week of MSC2360844 treatment. Each dot
represents one mouse. Bar represents mean value. (I) Relationship
between PD marker pAkt and UPCR. The pAkt PK/PD model was used
to mimic pAkt response under efficacy experiment conditions.
*p<0.05, **p<0.01, ***p< 0.001.
Table 2 | Numbers of lymphocyte subsets in spleen at end of the treatment.
No. of cells
(×106) (mean±SD)
Sham Vehicle MMF MSC2360844
6.6 mg/kg
MSC2360844
22 mg/kg
MSC2360844
66 mg/kg
MSC2360844
66 mg/kg (L)
Total splenocytes 33.34* (± 12.53) 51.94 (± 19.70) 46.50 (± 25.17) 51.90 (± 25.17) 46.64 (± 21.37) 38.41 (± 11.39) 37.79 (± 15.17)
B220+CD19+ (total
B cells)
13.28* (± 7.16) 24.92 (± 9.89) 20.65 (± 6.54) 24.52 (± 13.69) 21.75 (± 11.10) 18.07 (± 5.91) 16.08 (± 8.59)
CD138+ (plasma cells) 0.22* (± 0.23) 0.84 (± 0.32) 0.43 (± 0.28) 0.67 (± 0.50) 0.52 (± 0.54) 0.23* (± 0.13) 0.27* (± 0.28)
GL-7+IgG− (GC B cells) 0.18 (± 0.20) 0.46 (± 0.22) 0.23 (± 0.16) 0.49 (± 0.18) 0.42 (± 0.24) 0.18 (± 0.11) 0.20 (± 0.15)
IgG+ (class-switched
B cells)
0.13 (± 0.07) 0.24 (± 0.18) 0.17 (± 0.05) 0.18 (± 0.13) 0.19 (± 0.08) 0.12* (± 0.03) 0.13 (± 0.07)
CD3+ (total T-cells) 16.26 (± 3.83) 15.90 (± 4.75) 21.05 (± 6.83) 19.44 (± 5.39) 21.22 (± 5.95) 17.90 (± 5.57) 16.29 (± 4.69)
CD4+ CD44low
CD62Lhigh (naive CD4+
T-cells)
5.39 (± 1.32) 3.50 (± 1.53) 6.77* (± 2.57) 6.03 (± 1.64) 7.08* (± 1.35) 6.59* (± 2.43) 5.61 (± 1.62)
CD4+ CD44high
CD62Llow (activated
CD4+ T-cells)
3.38* (± 1.82) 7.23 (± 3.00) 5.24 (± 2.05) 6.10 (± 4.51) 5.30 (± 3.19) 3.03* (± 1.31) 3.44 (± 2.23)
CD8+ CD44low
CD62Lhigh (naive CD8+
cells)
4.13* (± 1.12) 2.07 (± 0.80) 5.06* (± 1.76) 3.78 (± 0.95) 4.89* (± 1.89) 5.15 (± 1.74) 4.19* (± 1.37)
CD8+ CD44high
CD62Llow (activated
CD8+ T-cells)
0.18* (± 0.08) 0.46 (± 0.25) 0.23 (± 0.09) 0.33 (± 0.21) 0.34 (± 0.28) 0.21 (± 0.09) 0.26 (± 0.22)
Statistical analysis; one-way ANOVA followed by Dunnett’s test versus vehicle group. *p<0.05.
model. Mice were treated once daily for 2 weeks with MSC2360844
in early intervention. One hour after the last dosing, blood was
taken and stimulated ex vivo with anti-IgD. B220+ B cells were
then assessed for CD69 up-regulation. B cells form MSC2360844-
treated mice showing a significant, dose-dependent reduction of
CD69 surface expression, whereas B cells from MMF-treated mice
were indistinguishable from untreated mice (Figure 6H), indicat-
ing that MSC2360844 inhibited BCR-mediated early activation of
B cells in vivo whereas MMF affects B cell function via a different
pathway.
The established PK/PD model was next applied to simulate
pAkt response following repeated inhibitor treatment in the SLE
model. Areas under the effects of response (AUE) on pAkt over the
whole treatment period were estimated and correlated to UPCR.
A steep correlation between PD and efficacy was observed with
hill number of 3.9 with AUE50 at 24± 5% inhibition of pAkt over
24 h. These data suggest dosing of PI3Kδ inhibitor with 24% of
target coverage over 24 h is sufficient to achieve 50% efficacy, and
a complete inhibition of the disease can be achieved by 50% target
coverage over time in this SLE model (Figure 6I).
In summary, intervention with PI3Kδ inhibitors after break
down of tolerance, either at the onset of serum anti-dsDNA Ab or
the onset of proteinuria, significantly blocked disease progression
and kidney damage, similar to the benchmark immunosuppres-
sant drug MMF, in the ADV-IFNα-accelerated NZB/W F1 SLE
model.
DISCUSSION
We compared head-to-head two novel PI3Kδ inhibitors,
MSC2360844 and MSC2364588, in single cell type cultures and
BioMAP® co-culture systems. We confirmed a central role of
PI3Kδ in human B- and T-cell functions in conditions mimicking
autoimmune disease pathology without detectable signs of unde-
sired side effects. We also demonstrated that selective inhibition of
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PI3Kδ blocked disease progression and kidney damage in a mouse
model of SLE/lupus nephritis. These protective effects correlated
with reduced B- and T-cell activity, compound target coverage,
and levels of PD markers, pAkt, and CD69.
Our PI3Kδ inhibitors are derived from a thiochroman series.
MSC2360844 exhibited better DMPK properties but relatively
lower selectivity versus other PI3K isoforms (namely, PI3Kβ),
whereas MSC2364588 showed higher potency and selectivity
but relatively poorer DMPK properties. Evaluation of the two
compounds side-by-side in all assays allowed us to exemplify
PI3Kδ-specific functional effects.
The roughly 10-fold difference between MSC2360844 and
MSC2364588 in PI3Kδ inhibition, as shown in the enzymatic assay,
was consistently reproduced in all functional cell-based assays
(containing no or low plasma protein). This suggests strongly
that the cellular activity of both compounds was on-target. Tak-
ing into account differential plasma protein binding, clearance,
and oral bioavailability of the two compounds, this relationship
was also preserved in whole blood and in vivo. These data con-
firm MSC2360844 and MSC2364588 as selective and potent PI3Kδ
inhibitors in vitro and in vivo.
In line with the reported roles of PI3Kδ, our compounds exhib-
ited strong effects in human B- and T-cell and pDC functional
assays. In addition, they were also efficacious in suppressing Ab and
pro-inflammatory cytokine production in the BioMAP® B–T co-
culture system, suggesting PI3Kδ inhibition can block interdepen-
dent B- and T-cell responses under pathophysiological conditions
in immune-mediated inflammatory diseases.
IFNα-inducible gene signature has been associated with
patients with severe SLE (18, 19) and exogenous IFNα can induce
autoimmunity in humans, including SLE (22). We chose to evalu-
ate the in vivo efficacy of our compounds in an IFNα-accelerated
murine SLE model. Exposure of lupus-prone NZB/W F1 mice
to IFNα leads to an accelerated and synchronized disease onset,
increased disease severity, and lower survival rate (21). While
untreated NZB/W F1 mice go into long-term remission following a
short course of combined cyclophosphamide, CTLA4-Ig and anti-
CD40L treatment, adenovirus (ADV)-IFNα-accelerated NZB/W
F1 mice are only transiently affected (23), demonstrating the sever-
ity of the disease in this model, possibly representing the subset
of SLE patients with IFNα-gene signature. We adapted the model
form Mathian et al. with a modified protocol applying a single
i.v. injection of 1× 108 IU/100µl of ADV-IFNα which resulted in
the appearance of serum anti-dsDNA antibodies at week 2, pro-
teinuria at week 4, and no mortality by week 10. Interestingly, at
the time of anti-dsDNA appearance, the expansion of ASCs and
a small number of IL-17- but not IFNγ- or TNFα-producing T-
cells were detectable; whereas at the onset of proteinuria, both
ASCs and a large number of IL-17-, IFNγ-, and TNFα-producing
T-cells were present in the spleen (Figure S5 in Supplementary
Material). Likewise, patients with SLE have increased numbers of
IL-17-producing cells and an elevated level of IL-17 in the serum,
and IL-17-producing cells in affected kidneys (17, 24). It is possible
that IL-17-producing cells, as opposed to other T-cell subsets, are
early participants in mounting the immune response in periph-
eral lymphoid tissues (25, 26) and target organs in these patients.
Recently, it has been shown that increased Th17 cells correlates
with IFN type 1-inducible signature in SLE patients (27). Taken
together, the ADV-IFNα-accelerated NZB/W F1 mouse model
likely represents a subset of SLE patients with severe disease activ-
ity, IFNα-signature, and engaged IL-17 pathway in addition to
active B cell involvement with elevated anti-dsDNA Ab titers.
Although both B- and T-cells are thought to be key players,
our understanding of the molecular pathophysiology of SLE and
lupus nephritis is still incomplete. Belimumab (anti-BAFF/BLYSS
Ab), the first new approved drug for SLE in more than 50 years,
appears to show modest efficacy and is indicated as add-on ther-
apy in patients with active SLE receiving standard therapy, thus
excluding active lupus nephritis and neuropsychiatric lupus (3).
MMF, although generally effective, both as induction and mainte-
nance therapy, for patients with severe SLE manifestations includ-
ing lupus nephritis, comes with long-term safety concerns (25).
Comparable to the efficacy of MMF and a BAFF blocker, our com-
pounds dose-dependently prevented the development of protein-
uria and kidney lesions in the ADV-IFNα-accelerated lupus model
when administered at the onset of autoantibody production. Inter-
estingly, at the onset of proteinuria, only PI3Kδ inhibitors and
MMF but not BAFF blocker was efficacious in preventing disease
progression. Our data therefore suggest that, despite the presence
of IL-17-producing T-cells, B cells play a central role in the early
phase of the disease, which can be blocked with B cell modulators;
at the time when kidney function becomes compromised, the dis-
ease is driven by both B- and T-cells and thus only therapeutics
that block both cell activities, including cytokine production, such
as PI3Kδ inhibitors or MMF, can be effective.
Anti-dsDNA Abs are routinely measured to monitor disease
activity in SLE and have been associated with severe manifes-
tations of lupus such as glomerulonephritis (28). MSC2360844
treatment in the IFNα-accelerated SLE model led to a decrease in
numbers of ASCs (Figure 6F), CD138+ plasma cells, IgG+ class-
switched B cells (Table 2) in the spleen as well as a decrease in
IgG2 depositions in the kidney (Figure 6D). However, no statis-
tically significant reduction of anti-dsDNA Ab serum levels was
observed as is the case of MMF treatment (Figure 6G). The dis-
crepancy between tissue and blood Ab levels may be attributed to:
(1) the fact that IFNα-accelerated NZBxW F1 mice are more resis-
tant to treatment than other SLE models (23), probably because
IFNα is potentiating T and B cell functions including class-switch
and IgG production (29, 30); (2) the possibility that different B cell
compartments are the source of IgG deposited in the kidney and
serum anti-dsDNA Abs; (3) the possibility that the IgG deposition
in the kidney is less dependent on serum antibody levels, than it
is on other unknown factors; (4) a too short observation period
under treatment given a long circulating Ab half-life.
Similarly, elevated serum anti-dsDNA Ab levels have been
detected in patients in the absence of any SLE flare or detectable
disease activity (31). Likewise, the clinical efficacy of rituximab
in SLE correlates with B cell depletion and precedes by several
months any decline in autoantibodies (32). Our data further sup-
port that serum anti-dsDNA Ab titers do not always correlate
with immune-complex deposition in the kidney or lupus nephritis
disease activity following short-term immune modulation.
It is noteworthy that in this disease model, PI3Kδ inhibi-
tion restored homeostasis of lymphocyte populations in the
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spleen: hyperactive B-, T-, and plasma cells were reduced, whereas
naïve B- and T-cell numbers were restored to normal levels.
This is in contrast to mice deficient for PI3Kδ function show-
ing reduced numbers of B cell precursors and mature B cells
in the spleen (16, 33). These data suggest that PI3Kδ inhibition
ameliorates SLE-like disease via immunomodulation rather than
immunosuppression.
It should be mentioned that dysfunction of Tregs and AICD of
T-cells have also been observed in SLE patients (8, 34, 35). Since
PI3Kδ has been demonstrated to be important for Treg develop-
ment and function in mice (36) and confers resistance to T-cell
AICD in SLE patients (8), future studies addressing the effects of
these PI3Kδ inhibitors on AICD and especially on human Tregs
are warranted.
PK/PD relationship studies during pre-clinical drug develop-
ment have the potential to significantly accelerate and reduce
the cost of clinical development by providing early dose guid-
ance for safety and efficacy (37). The consistent application of
pAkt and CD69 as PI3Kδ PD biomarkers in mouse and human,
a whole blood assay format throughout our pre-clinical studies
not only validated their biological relevance, but also allowed
us to determine the exposure–effect relationship and the corre-
lation between PI3Kδ inhibition and efficacy in the disease model.
Our data showed that an overall target coverage of 24% was
sufficient to achieve 50% of clinical efficacy, while 50% target
coverage was sufficient to achieve full clinical efficacy poten-
tial in the ADV-IFNα-accelerated lupus model. This is further
supported by a study in which PI3Kδ activity was genetically
attenuated to 50% in Lyn-deficient mice. These mice, which
normally develop spontaneously a severe form of lupus nephri-
tis, now showed significantly reduced kidney pathology (9).
Thus, our data provide measurable PD markers and guidance
for clinical study design aiming at achieving anticipated efficacy
while keeping potential safety issues due to excessive dosing at
bay.
While preparing this manuscript, two recent publications
report that a novel PI3Kδ and PI3Kγ dual inhibitor suppresses
anti-dsDNA Ab development and kidney dysfunction in the
NZB/W F1 lupus nephritis model (38). This protective effect
may be due to PI3Kδ inhibition since a selective PI3Kδ inhibitor
IC87114 decreases autoantibody production and kidney pathol-
ogy in another SLE-like model, BXSB mice (39). Our data largely
corroborate these findings, except that we did not observe a sig-
nificant dose-dependent reduction of anti-dsDNA Ab in serum
after 10 weeks of treatment. The discrepancy may due to differ-
ent SLE models and/or different treatment regimens. It is possible
that prolonged MSC2360844 treatment would lead to a significant
decrease of serum anti-dsDNA titer (32). Taken together, PI3Kδ
inhibition demonstrated efficacy in three SLE mouse models; these
data collectively support a critical role of PI3Kδ in the pathogenesis
of SLE/lupus nephritis.
In summary, targeted PI3Kδ inhibition dampens kidney disease
manifestation in SLE models through down-regulation of abnor-
mal B-, T-, and pDC cell function and re-establishes immune cell
homeostasis. We propose PI3Kδ inhibitors as potential therapeu-
tics for treating patients with SLE and lupus nephritis, and possibly
other autoimmune diseases.
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